The annual conference for contract pharmaceutical manufacturing partners returns to Pennsylvania, centering on regulatory shifts, AI and biotech innovation.

trade show concept

CPHI Americas 2026 is back in Philadelphia on 2-4 June, offering a platform for senior leaders across the pharmaceutical supply chain to discuss regulatory change, AI and biotech innovation.

It serves as an opportunity for manufacturers, biotech companies, suppliers, and service providers to network, share insights, and explore strategies to address industry-wide challenges.

The conference agenda covers key themes shaping the sector, including contract manufacturing, evolving regulatory frameworks, artificial intelligence, and innovation in biologics and advanced therapies.

As a hot industry topic, the conference will feature sessions on regulatory unpredictability, exploring changes in US policy and approaches to risk-based decision-making. These include:

  • FDA in Flux: Navigating The New Regulatory Landscape, featuring former US Department of Health and Human Services official Molly Klote
  • Global risk management and risk-to-value transformation, led by Patrick Day, Principal Consultant at Lachman Consultants.

As investment in biologics accelerates, speakers will also examine the future of biotech innovation and funding strategies. Sessions include:

  • The Evolving Biotech Innovation Ecosystem: What’s Ahead? with Murray Aitken, Executive Director at the IQVIA Institute
  • Fuelling Biotech Breakthroughs, featuring leaders from Likarda, BioLabs, Epivax and Morgan Stanley
  • Revolutionising Medicine: The Evolving Landscape of Cell & Gene Therapy in the US.

As global supply chains continue to face growing pressure, sessions will focus on procurement strategies and external manufacturing models. These include:

  • Building Resilient Supply Chains: Bayer’s Best Practices in Procurement and External Manufacturing, presented by Luiz Barberini
  • The Future of Strategic Alliances in Pharma, led by Mayank Nagar of Dr Reddy’s.

Digitalisation and cybersecurity remain critical priorities. Sessions will address supply chain threats, digital infrastructure and artificial intelligence (AI) in drug discovery, including:

  • Protecting Pharma: Ransomware, Social Engineering & Supply-Chain Threats, featuring the US Secret Service
  • Embedding AI Across Drug Discovery, led by Emily Lewis of UCB.

As the market landscape evolves and competition intensifies, the conference will also examine strategies for differentiation and communication.

  • Future Market Strategy - Winning the Narrative as a Manufacturing Partner, featuring speakers from Bandwidth Solutions, LGM Pharma and Veranova.

This year’s agenda focuses on the areas having the greatest impact on the sector, including regulatory shifts, AI and biologics”

 

Sarah Griffin, Event Manager at CPHI Americas, said: “CPHI Americas brings together leaders throughout the pharmaceutical supply chain to address the challenges shaping drug development and manufacturing.

She added: “This year’s agenda focuses on the areas having the greatest impact on the sector, including regulatory shifts, AI and biologics, providing attendees with practical insight they can apply within their organisations.”

Registration for CPHI Americas 2026 is now open. To access the full conference agenda, click here.

Topics